<p>SUPPORT OUR WORK AND GET MORE NEWS!<br />
https://linktr.ee/manonthemounjaro</p>

Zepbound’s 12.5 and 15 mg vials are finally being released—but there’s a catch that could cost you over $1,000 if you miss it. We also break down Amycretin’s jaw-dropping 24% weight loss data and Novo’s surprising leap straight to Phase 3. Plus, a new FDA program could fast-track future obesity drugs like CagriSema and Retatrutide. And finally, we issue a serious warning about the rise of research-grade cagrilintide being injected at home. This one’s packed. Let’s go.

Zepbound Vials Drop, Amycretin Surges, FDA Fast Track, and a Dangerous Trend // TWD 6.17.25